SER - Serina Therapeutics Inc.
Close
7.98
-0.020 -0.251%
Share volume: 3,785
Last Updated: Fri 30 Aug 2024 10:30:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$8.00
-0.02
-0.25%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-12 | 2022-11-10 | 2023-03-31 | 2023-05-12 | 2023-08-14 | 2023-11-14 | 2024-03-22 | 2024-05-14 | |
| Total revenue | 12.000 K | 9.000 K | 8.000 K | 10.000 K | 9.000 K | 67.000 K | 56.000 K | 5.000 K | |
| Cost of revenue | 6.000 K | 5.000 K | 3.000 K | 1.000 K | 5.000 K | 33.000 K | 1.000 K | 0.000 | |
| Gross profit | 6.000 K | 4.000 K | 5.000 K | 9.000 K | 4.000 K | 34.000 K | 55.000 K | 5.000 K | |
| -33.33% | 25.00% | 80.00% | -55.56% | 750.00% | 61.76% | -90.91% | |||
| Operating expenses | 1.597 M | 1.554 M | 1.789 M | 2.167 M | 1.890 M | 2.390 M | 3.615 M | 2.326 M | |
| Selling general and admin | 1.338 M | 1.392 M | 1.581 M | 1.993 M | 1.730 M | 2.172 M | 3.433 M | 1.220 M | |
| Research and development | 259.000 K | 162.000 K | 208.000 K | 174.000 K | 160.000 K | 218.000 K | 182.000 K | 1.106 M | |
| Total expenses | 1.603 M | 1.559 M | 1.792 M | 2.168 M | 1.895 M | 2.423 M | 3.616 M | 2.326 M | |
| -2.74% | 14.95% | 20.98% | -12.59% | 27.86% | 49.24% | -35.67% | |||
| Operating income | -1.591 M | -1.550 M | -1.784 M | -2.158 M | -1.886 M | -2.356 M | -3.560 M | -2.321 M | |
| Ebit | -1.591 M | -1.550 M | -1.784 M | -2.158 M | -1.886 M | -2.356 M | -3.560 M | -2.321 M | |
| Pretax income | -2.618 M | -2.436 M | -2.763 M | -3.285 M | -2.679 M | -5.389 M | -3.458 M | -9.437 M | |
| -6.95% | 13.42% | 18.89% | -18.45% | 101.16% | -35.83% | 172.90% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -2.618 M | -2.435 M | -2.703 M | -3.277 M | -2.669 M | -5.401 M | -3.456 M | -9.437 M | |
| 6.99% | -11.01% | -21.24% | 18.55% | -102.36% | 36.01% | -173.06% | |||
| Net income | -2.618 M | -2.435 M | -2.703 M | -3.277 M | -2.669 M | -5.401 M | -3.456 M | -9.437 M | |
| 6.99% | -11.01% | -21.24% | 18.55% | -102.36% | 36.01% | -173.06% |